Julius Clinical, a leading full-service Contract Research Organization headquartered in the Netherlands, and Peachtree BioResearch Solutions, a specialized CNS CRO based in the United States , announce they have merged as a fully integrated clinical research organization. The merger combines scientific and operational excellence, an expanded international footprint and increased capabilities across therapeutic areas, particularly within CNS.
Health Technology Insights: John Morris Joins Guidehouse to Lead Global Health Segment
Building on nearly a decade of successful collaboration between the two companies, the merged organization creates a comprehensive clinical CRO, bringing together extensive expertise in managing Phase I – III clinical trials with particular depth in central nervous system (CNS), cardio-metabolic, renal and rare diseases. Their combined strength delivers end-to-end clinical research services, enhanced global access in Europe and North America, and robust scientific expertise tailored to pharmaceutical-, biotech-, and medical device companies.
“We are thrilled to merge with Peachtree BioResearch Solutions,” says Martijn Wallert, Chief Executive Officer of Julius Clinical. “This marks a significant step forward in expanding our presence and deepening our capabilities across North America and Europe. This natural evolution of our long-term successful relationship allows us to leverage our aligned strengths to become a more versatile and capable partner for our clients.”
Health Technology Insights: Aranscia Acquires Spesana
“This merger represents a transformative opportunity for Peachtree, our dedicated team, and the clients we serve,” says Kristy Nichols, Chief Executive Officer of Peachtree BioResearch Solutions. “By joining forces with Julius Clinical, we are significantly expanding our capabilities, offering our clients access to an established international network while preserving the personalized approach we are known for.”
This strategic move, combining global reach with the flexibility of a highly specialized provider, positions Julius Clinical and Peachtree BioResearch Solutions to better address the increasing complexity and borderless nature of modern clinical research as they work together with innovators to advance therapies to patients worldwide.
Julius Clinical is supported by Ampersand Capital Partners, a leading private equity firm specializing in growth equity investments in the life sciences and healthcare sectors.
Health Technology Insights: Marana Health Chooses athenahealth to Enhance Patient and Clinician Experience
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source – PR Newswire
